Ost-müük First Wave BioPharma, Inc. - FWBI CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.0808 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 0.001 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 2.6824 |
| Avatud* | 2.6819 |
| Aastane muutus* | 148.32% |
| Päeva ulatus* | 2.4446 - 2.6824 |
| 52 nädala ulatus | 2.68-289.80 |
| Keskmine maht (10 päeva) | 36.09K |
| Keskmine maht (3 kuud) | 11.17M |
| Turukapitalisatsioon | 4.20M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 1.55M |
| Tulu | N/A |
| EPS | -66.83 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.70 |
| Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Mar 29, 2023 | 2.4446 | -0.2376 | -8.86% | 2.6822 | 2.7713 | 2.4446 |
| Mar 28, 2023 | 2.6824 | -0.2082 | -7.20% | 2.8906 | 2.9003 | 2.6222 |
| Mar 27, 2023 | 2.9699 | 0.0004 | 0.01% | 2.9695 | 3.0093 | 2.8700 |
| Mar 24, 2023 | 2.9994 | 0.0199 | 0.67% | 2.9795 | 3.0290 | 2.9692 |
| Mar 23, 2023 | 3.0092 | -0.0587 | -1.91% | 3.0679 | 3.1978 | 2.9791 |
| Mar 22, 2023 | 3.0193 | -0.0990 | -3.17% | 3.1183 | 3.1774 | 2.9687 |
| Mar 21, 2023 | 3.1678 | 0.0892 | 2.90% | 3.0786 | 3.1678 | 3.0582 |
| Mar 20, 2023 | 3.0588 | 0.0499 | 1.66% | 3.0089 | 3.1283 | 2.9691 |
| Mar 17, 2023 | 3.0291 | 0.0600 | 2.02% | 2.9691 | 3.0391 | 2.9591 |
| Mar 16, 2023 | 2.9695 | 0.1986 | 7.17% | 2.7709 | 3.0093 | 2.7704 |
| Mar 15, 2023 | 2.9302 | 0.1883 | 6.87% | 2.7419 | 2.9302 | 2.6917 |
| Mar 14, 2023 | 2.7715 | -0.1685 | -5.73% | 2.9400 | 2.9400 | 2.6912 |
| Mar 13, 2023 | 3.0191 | -0.5440 | -15.27% | 3.5631 | 3.5731 | 2.9982 |
| Mar 10, 2023 | 3.6238 | 0.0103 | 0.29% | 3.6135 | 3.6634 | 3.5640 |
| Mar 9, 2023 | 3.7131 | -0.2472 | -6.24% | 3.9603 | 4.1786 | 3.5639 |
| Mar 8, 2023 | 3.5246 | -0.0395 | -1.11% | 3.5641 | 3.6041 | 3.4648 |
| Mar 7, 2023 | 3.5148 | -0.0593 | -1.66% | 3.5741 | 3.7130 | 3.5047 |
| Mar 6, 2023 | 3.6437 | 0.0800 | 2.24% | 3.5637 | 3.7130 | 3.5637 |
| Mar 3, 2023 | 3.6436 | 0.1790 | 5.17% | 3.4646 | 3.7723 | 3.4646 |
| Mar 2, 2023 | 3.5146 | 0.0496 | 1.43% | 3.4650 | 3.5546 | 3.4650 |
First Wave BioPharma, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 59.0569 | 26.8313 | 14.7437 | 13.4318 | 10.2212 |
| Müük/Üldine/admin kulud, kokku | 18.3696 | 7.27976 | 6.04227 | 8.17431 | 6.93171 |
| Uuringud ja arendus | 38.3204 | 19.105 | 7.85849 | 4.98555 | 2.39548 |
| Depreciation / Amortization | 0.015 | 0.048 | 0.84299 | 0.06191 | 0.754 |
| Other Operating Expenses, Total | 0 | 0.21 | 0.14 | ||
| Tulud majandustegevusest | -59.0569 | -26.8313 | -14.7437 | -13.4318 | -10.2212 |
| Intressitulud (kulu), muud tulud, neto | -0.01007 | -5.84013 | -0.43394 | -0.10185 | -0.8752 |
| Muud, neto | 0.5291 | 0 | |||
| Netotulu enne makse | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Netotulu pärast makse | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Netotulu enne erikulusid | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Netotulu | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Arvestatav tulu, v a erikulud | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Arvestatav tulu, koos erikuludega | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Jaotamisele kuuluv netotulu | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Keskmine jaotamisele kuuluv aktsia kohta | 0.0425 | 0.01354 | 0.01068 | 0.00735 | 0.00506 |
| Jaotatav EPS, v a erakorralised kulud | -1988.67 | -3082.15 | -1421.4 | -1840.94 | -2192.55 |
| Jaotamisele kuuluv normaal-EPS | -1933.33 | -3052.71 | -1421.4 | -1840.94 | -2192.55 |
| Tulu | 0 | ||||
| Ootamatud kulutused (tulu) | 2.35199 | 0.39857 | |||
| Total Adjustments to Net Income | -25.9807 | -9.06087 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | -4.38953 | 14.7879 | 9.38207 | 11.167 | 30.3995 |
| Müük/Üldine/admin kulud, kokku | 2.90445 | 6.90451 | 4.40556 | 3.03678 | 6.02116 |
| Uuringud ja arendus | 0.79107 | 7.88341 | 4.97652 | 5.77821 | 24.3783 |
| Depreciation / Amortization | |||||
| Tulud majandustegevusest | 4.38953 | -14.7879 | -9.38207 | -11.167 | -30.3995 |
| Intressitulud (kulu), muud tulud, neto | 0.0018 | -0.00775 | -0.00547 | -0.00123 | -0.00074 |
| Muud, neto | 0 | -0.2393 | -0.2393 | -0.00428 | -0.00057 |
| Netotulu enne makse | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Netotulu pärast makse | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Netotulu enne erikulusid | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Netotulu | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Total Adjustments to Net Income | -0.15758 | -0.18792 | -0.09079 | -0.11623 | -0.11809 |
| Arvestatav tulu, v a erikulud | 4.23375 | -15.2229 | -9.71763 | -11.2887 | -30.5189 |
| Arvestatav tulu, koos erikuludega | 4.23375 | -15.2229 | -9.71763 | -11.2887 | -30.5189 |
| Jaotamisele kuuluv netotulu | 4.23375 | -15.2229 | -9.71763 | -11.2887 | -30.5189 |
| Keskmine jaotamisele kuuluv aktsia kohta | 0.23225 | 0.18244 | 0.09642 | 0.06153 | 9.34236 |
| Jaotatav EPS, v a erakorralised kulud | 18.2291 | -83.4388 | -100.782 | -183.468 | -3.26672 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | 18.2291 | -83.4388 | -100.782 | -145.242 | -3.26672 |
| Ootamatud kulutused (tulu) | 2.35199 | ||||
| Other Operating Expenses, Total | -8.08505 | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 9.42495 | 7.86978 | 3.40829 | 4.8 | 1.95257 |
| Raha ja lühiajalised investeeringud | 8.24868 | 6.06214 | 0.1758 | 1.11434 | 0.57347 |
| Cash | 8.24868 | 6.06214 | 0.1758 | 1.11434 | 0.57347 |
| Lühiajalised investeeringud | |||||
| Laekumata arved, neto | 0 | 0.55149 | 2.6373 | 3.17268 | 1.10413 |
| Prepaid Expenses | 1.17627 | 1.25615 | 0.59519 | 0.51298 | 0.27496 |
| Total Assets | 11.79 | 12.9239 | 8.90288 | 7.4694 | 5.47967 |
| Property/Plant/Equipment, Total - Net | 0.40931 | 0.09257 | 0.15978 | 0.12885 | 0.13399 |
| Goodwill, Net | 1.91171 | 2.05405 | 1.88669 | 1.92483 | 2.01624 |
| Intangibles, Net | 0 | 2.87954 | 3.40708 | 0.57048 | 1.34596 |
| Other Long Term Assets, Total | 0.04401 | 0.02792 | 0.04105 | 0.04523 | 0.03092 |
| Total Current Liabilities | 12.3004 | 15.5454 | 4.28564 | 2.99552 | 2.47908 |
| Payable/Accrued | 0 | 0.53343 | 0.6701 | 2.05534 | |
| Accrued Expenses | 0.49706 | 0.18443 | 0.15441 | 0.53829 | 0.00719 |
| Notes Payable/Short Term Debt | 0.64124 | 0.55241 | 1.5213 | 0.25503 | 0.41655 |
| Other Current Liabilities, Total | 8.48018 | 13.25 | 0.39299 | ||
| Total Liabilities | 19.6115 | 15.5646 | 4.28564 | 2.99552 | 3.81908 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 7.31114 | 0.01912 | 0 | 0 | 1.34 |
| Total Equity | -7.82155 | -2.64069 | 4.61724 | 4.47387 | 1.66059 |
| Common Stock | 0.00149 | 0.00312 | 0.00268 | 0.00177 | 0.00121 |
| Additional Paid-In Capital | 147.305 | 93.8349 | 68.5759 | 53.1393 | 37.6696 |
| Retained Earnings (Accumulated Deficit) | -153.904 | -95.3662 | -62.6947 | -47.5171 | -33.9834 |
| Other Equity, Total | -1.22414 | -1.11255 | -1.26656 | -1.15011 | -2.02679 |
| Total Liabilities & Shareholders’ Equity | 11.79 | 12.9239 | 8.90288 | 7.4694 | 5.47967 |
| Total Common Shares Outstanding | 14.8559 | 3.11503 | 2.68005 | 1.77049 | 1.20426 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Property/Plant/Equipment, Total - Gross | 0.42402 | 0.13097 | 0.4233 | 0.33225 | |
| Accumulated Depreciation, Total | -0.01471 | -0.0384 | -0.26352 | -0.20339 | |
| Accounts Payable | 2.68191 | 1.55859 | 1.68351 | 1.53211 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 6.55017 | 9.42495 | 7.50249 | 8.61528 | 13.1704 |
| Raha ja lühiajalised investeeringud | 5.69499 | 8.24868 | 7.21065 | 8.07449 | 12.0256 |
| Cash | 5.69499 | 8.24868 | 7.21065 | 8.07449 | 12.0256 |
| Laekumata arved, neto | 0.02806 | 0 | 0 | 0 | 0.50166 |
| Prepaid Expenses | 0.82713 | 1.17627 | 0.29184 | 0.54079 | 0.64313 |
| Total Assets | 8.82544 | 11.79 | 12.424 | 13.7768 | 17.9829 |
| Property/Plant/Equipment, Total - Net | 0.3788 | 0.40931 | 0.44889 | 0.48488 | 0.06162 |
| Property/Plant/Equipment, Total - Gross | 0.40083 | 0.42402 | 0.45632 | 0.4861 | 0.0812 |
| Accumulated Depreciation, Total | -0.02203 | -0.01471 | -0.00743 | -0.00123 | -0.01958 |
| Goodwill, Net | 1.86207 | 1.91171 | 1.94474 | 1.99129 | 1.97396 |
| Intangibles, Net | 0 | 2.48388 | 2.61576 | 2.74765 | |
| Other Long Term Assets, Total | 0.0344 | 0.04401 | 0.04403 | 0.0696 | 0.02924 |
| Total Current Liabilities | 14.2157 | 12.3004 | 19.0983 | 6.45412 | 3.57464 |
| Accounts Payable | 3.44993 | 2.68191 | 18.4478 | 4.44991 | 1.44072 |
| Accrued Expenses | 0.7883 | 0.49706 | 0.22987 | 0.31246 | 0.32383 |
| Notes Payable/Short Term Debt | 0.40277 | 0.64124 | 0 | 0.13957 | 0.34708 |
| Other Current Liabilities, Total | 9.57473 | 8.48018 | 0.42063 | 1.55218 | 1.46302 |
| Total Liabilities | 18.0652 | 19.6115 | 19.394 | 6.73988 | 3.58121 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.8495 | 7.31114 | 0.29569 | 0.28575 | 0.00657 |
| Total Equity | -9.23979 | -7.82155 | -6.96999 | 7.03692 | 14.4017 |
| Common Stock | 0.00215 | 0.00149 | 0.00111 | 0.00826 | 0.00749 |
| Additional Paid-In Capital | 155.571 | 147.305 | 137.028 | 120.585 | 118.693 |
| Retained Earnings (Accumulated Deficit) | -163.531 | -153.904 | -142.732 | -112.331 | -103.052 |
| Other Equity, Total | -1.28254 | -1.22414 | -1.26711 | -1.2255 | -1.24734 |
| Total Liabilities & Shareholders’ Equity | 8.82544 | 11.79 | 12.424 | 13.7768 | 17.9829 |
| Total Common Shares Outstanding | 21.5488 | 14.8559 | 11.1152 | 8.25851 | 7.49269 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Raha majandustegevusest | -32.2882 | -11.2215 | -14.0335 | -10.8693 | -7.18464 |
| Raha majandustegevusest | 0.01471 | 0.0378 | 0.0631 | 0.06191 | 0.04952 |
| Amortization | 0.52755 | 0.52755 | 0.95695 | 0.73654 | 0.70448 |
| Mittelikviidsed varad | 8.60641 | 6.73365 | 1.82513 | 3.57765 | 3.42595 |
| Muutused tööjõus | 17.101 | 14.1509 | -1.70099 | -1.7118 | -0.26821 |
| Tulu investeeringutelt | -10.3195 | 0.08735 | -0.0241 | -0.30547 | -0.03217 |
| Kapitalikulutused | -0.06949 | -0.00417 | -0.0241 | -0.30547 | -0.03217 |
| Rahavood investeeringutelt | 44.7635 | 17.0461 | 13.145 | 11.7121 | 6.01322 |
| Rahavoogudesse investeerimine | 0 | ||||
| Aktsiate emiteerimine (tagasiost), neto | 44.6747 | 14.1861 | 9.53834 | 11.9028 | 5.00923 |
| Laenu väljastamine (kustutamine), neto | 0.08883 | 2.86003 | 3.60664 | -0.19068 | 1.00399 |
| Muutused valuutakursside kõikumisest | 0.03076 | -0.02559 | -0.02593 | 0.00354 | 0.00353 |
| Rahaline kogumuutus | 2.18654 | 5.88635 | -0.93855 | 0.54087 | -1.20005 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | |
| Makstud intressid | 0 | 0.10546 | 0.00803 | 0.00401 | 0.00415 |
| Muud rahavood investeeringutelt, kokku | -10.25 | 0.09152 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.62684 | -58.5378 | -47.3654 | -16.9646 | -7.68563 |
| Cash From Operating Activities | -7.91207 | -32.2882 | -26.4254 | -10.6961 | -5.07339 |
| Cash From Operating Activities | 0.00732 | 0.01471 | 0.00939 | 0.00301 | 0.00102 |
| Amortization | 0 | 0.52755 | 0.39566 | 0.26377 | 0.13189 |
| Non-Cash Items | 0.36042 | 8.60641 | 2.04186 | 1.7359 | 1.80638 |
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0.00514 |
| Changes in Working Capital | 1.34703 | 17.101 | 18.493 | 4.26576 | 0.67294 |
| Cash From Investing Activities | -10.3195 | -10.3215 | -9.07393 | 0 | |
| Capital Expenditures | -0.06949 | -0.07145 | -0.07393 | 0 | |
| Cash From Financing Activities | 5.36715 | 44.7635 | 37.9406 | 21.8326 | 11.0506 |
| Financing Cash Flow Items | -2.41496 | -9.53235 | |||
| Issuance (Retirement) of Stock, Net | 8.02057 | 44.6747 | 38.493 | 22.2454 | 20.7883 |
| Issuance (Retirement) of Debt, Net | -0.23847 | 0.08883 | -0.55241 | -0.41284 | -0.20532 |
| Foreign Exchange Effects | -0.00877 | 0.03076 | -0.04525 | -0.05019 | -0.01374 |
| Net Change in Cash | -2.5537 | 2.18654 | 1.1485 | 2.01235 | 5.96349 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | -10.25 | -10.25 | -9 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Armistice Capital LLC | Hedge Fund | 2.7101 | 41995 | 41995 | 2022-12-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.7614 | 11799 | 0 | 2022-12-31 | LOW |
| Sapirstein (James E) | Individual Investor | 0.6914 | 10714 | -32143 | 2023-03-16 | HIGH |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.4632 | 7178 | 7178 | 2022-12-31 | MED |
| Romano (Sarah M.) | Individual Investor | 0.3457 | 5357 | -16072 | 2023-03-16 | MED |
| Hoffman (David Andrew) | Individual Investor | 0.2509 | 3888 | -9080 | 2023-03-16 | HIGH |
| Borkowski (Edward J) | Individual Investor | 0.2083 | 3228 | -9080 | 2023-03-16 | LOW |
| Riddell (Alastair) | Individual Investor | 0.1993 | 3089 | -9080 | 2023-03-16 | HIGH |
| Casamento (Charles J) | Individual Investor | 0.1989 | 3082 | -9080 | 2023-03-16 | LOW |
| Coelho (Mary Theresa) | Individual Investor | 0.1953 | 3027 | -9079 | 2023-03-16 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.1408 | 2182 | 2182 | 2022-12-31 | MED |
| UBS Financial Services, Inc. | Investment Advisor | 0.1315 | 2038 | 1752 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0987 | 1529 | 1529 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.063 | 977 | 0 | 2023-02-28 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0626 | 970 | 497 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0243 | 377 | 0 | 2022-12-31 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.0185 | 286 | 286 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.0017 | 27 | 0 | 2022-12-31 | LOW |
| U.S. Bancorp Asset Management, Inc. | Investment Advisor | 0.0015 | 24 | 0 | 2022-12-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.0014 | 22 | 0 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
First Wave BioPharma, Inc. Company profile
Ettevõttest First Wave BioPharma, Inc.
First Wave BioPharma, Inc., varem AzurRx BioPharma, Inc., on kliinilise faasi biofarmatseutiline ettevõte. Ta tegeleb sihtotstarbeliste, mittesüsteemsete ravimeetodite väljatöötamisega seedetrakti haiguste raviks. Ettevõte keskendub terapeutiliste ravimite arendamisele, mis põhineb kahel tehnoloogial: niklosamiid, suukaudne väike molekul, millel on viirusevastased ja põletikuvastased omadused, ja bioloogiline adrulipaas, rekombinantse lipaasi ensüüm, mis on mõeldud rasvade ja muude toitainete seedimise võimaldamiseks. Ettevõtte niklosamiidiportfelli juhivad kolm kliinilist programmi: FW-COV, COVID-19 seedetrakti infektsioonide puhul; FW-UP, haavandilise proktiidi (UP) ja haavandilise proktosigmoidiidi puhul; ja FW-ICI-AC, 1. ja 2. astme immuunsüsteemi kontrollpunkti inhibiitoriga seotud koliit ja kõhulahtisus kaugelearenenud onkoloogilistel patsientidel. Samuti edendab ta FW-EPI (adrulipaas) eksokriinset pankreasepuudulikkust (EPI) tsüstilise fibroosi ja kroonilise pankreatiidi patsientidel.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com